Forteo Patient Registry Progress Page

At the conclusion of the study, 75,247 people had signed up to join the Forteo Patient Registry. Patient enrollment into the study is now closed.

When Will Results be Available?

A summary of the study progress, including the number of patients enrolled in the Registry and the incidence of osteosarcoma (which is based on the latest cancer registry linkage) was submitted to Eli Lilly and Company quarterly through the end of patient enrollment. The final study results were published in a medical journal in November 2020 (please see link to the article below). None of these reports provide identifying data on individual patients.

Related Publications

  1. Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporosis International 2020.

  2. Gilsenan, A., Midkiff, K., Harris, D., Kellier-Steele, N., McSorley, D. Andrews, E.B. (2020). Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res.

  3. Gilsenan, A., Midkiff, K., Harris, D., McQuay, L., Hunter, S., Kellier-Steele, Andrews, E. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry data. Pharmacoepidemiol Drug Saf. 2020;1-11.

  4. Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporosis International 2018; 29:2335-2343. [PDF]

  5. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27(12):2429-37.